Meeting
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
Authors
Yu Fujiwara
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Yu Fujiwara , Mako Koseki , Jonathan Estaris , Evelyn Elias , Fnu Chesta , Kensuke Takaoka , Yoshito Nishimura , Dharmesh Gopalakrishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 604)
DOI
10.1200/JCO.2024.42.4_suppl.604
Abstract #
604
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.
First Author: Giuseppe Viscardi
Poster
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
First Author: Peter Zang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Genitourinary Cancers Symposium
Exploratory analysis of predictive biomarkers for immune-related adverse events (irAEs) due to checkpoint inhibitors (CPIs) in patients with genitourinary (GU) cancers.
First Author: Elham Vosoughi